drugset / Trial / NCT07285798

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

NCT07285798

Phase 3 Not yet recruiting 176 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.

Timeline

Start
2026-09-11
Primary completion
2029-08-04
Completion
2029-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject KarX-EC Unknown
Subject Trospium Small molecule